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A B S T R A C T
CCR4 is a chemokine receptor highly expressed by Th2 cells, and regarded as a potential therapeutic target for
atopic dermatitis (AD). CCL17 and CCL22 are the CCR4 ligands, and thymic stromal lymphopoietin (TSLP) is
shown to promote the expression of CCL17 and CCL22 by dendritic cells. Here, by using dibutyl phthalate (DBP),
a TSLP inducer, and a hydrogel patch as a transcutaneous delivery device for ovalbumin, we developed a novel
murine AD model and investigated the effect of Compound 22, a CCR4 antagonist. We first found that the mRNA
expression of TSLP together with CCL17 and CCL22 was increased in the skins treated with DBP. Furthermore,
the topical application of ovalbumin and DBP efficiently and rapidly induced AD-like skin lesions in BALB/c
mice, which were characterized by ear swelling accompanied by infiltration of eosinophils, mast cells, and CCR4-
expressing Th2 cells in the skin lesions, and elevated total IgE levels in the sera. Using this AD model, we
demonstrated that cutaneous administration of Compound 22 inhibited Th2 cell infiltration and ameliorated the
AD-like skin lesions. These results suggest that our AD model could be useful for studying new therapeutic
strategies. Collectively, CCR4 antagonists may be a promising approach for treating AD.
1. Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin disease
characterized by pruritus and relapsing eczema, and is frequently as-
sociated with high serum IgE levels and eosinophilia [1,2]. In addition,
most AD patients have an increased number of T-helper (Th) 2 cells in
the skin lesions and peripheral blood [1–4]. Th2 cells produce IL-4, IL-
5, and IL-13, which are responsible for the promotion of IgE production
by B cells. Furthermore, mast cell-bound IgE leads to mast cell de-
granulation and initiates allergic reactions. CCR4 is a major trafficking
receptor for Th2 cells, and its ligands are TARC/CCL17 and MDC/
CCL22 [5]. Indeed, CCR4 is shown to be expressed on infiltrated Th2
cells in skin lesions of AD patients [6]. Furthermore, we and others have
shown that the serum levels of CCL17 and CCL22 are highly elevated in
AD patients and correlate positively with disease severity [7–9]. In this
context, a CCL17 ELISA kit (Alaport TARC) has been developed to ob-
jectively monitor the disease activity and therapeutic response of AD
patients. Thus, the CCR4 axis is now considered to play a pivotal role in
the pathogenesis of AD by recruiting CCR4-expressing Th2 cells.
Thymic stromal lymphopoietin (TSLP) is highly expressed by kera-
tinocytes in skin lesions of acute and chronic AD [10,11], and induces
the expression of Th2-type cytokines, such as IL-4, IL-5, and IL-13, and
Th2-attracting chemokines, such as CCL17 and CCL22, in dendritic cells
(DCs) [11,12]. Furthermore, it was reported that TSLP acted directly on
naïve CD4+T cells to promote Th2 differentiation during allergic in-
flammation in the skin [13]. Thus, TSLP is thought to be involved in the
induction of Th2 responses and the development of Th2-type allergic
diseases such as AD.
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Recently, dibutyl phthalate (DBP) was reported to induce TSLP
expression in keratinocytes of the skin and to be an adjuvant for FITC-
induced contact hyper sensitivity [14–16]. In addition, we developed a
hydrogel patch as an efficient transcutaneous immunization system,
and demonstrated that the hydrogel patch can efficiently promote skin
penetration of antigenic proteins [17–19]. Furthermore, by using the
hydrogel patch containing ovalbumin (OVA), we were able to induce
acute AD-like skin lesions only by three weeks in BALB/c mice [20]. In
the present study, we therefore combined DBP and the hydrogel patch
to develop a more efficient model of AD. Using this AD model, we also
demonstrated that cutaneous administration of Compound 22, a CCR4
antagonist, ameliorated the AD-like skin lesions.
2. Materials and methods
2.1. Mice
BALB/c mice were purchased from Japan SLC (Shizuoka, Japan).
Mice were maintained in specific pathogen-free conditions. All animal
experiments were approved by the Center of Animal Experiments,
Kindai University, and performed in accordance with the institutional
guidelines.
2.2. Hydrogel patch formulation
The hydrogel patch formulation, comprising cross-linked HiPAS™
acrylate medical adhesives (CosMED Pharmaceutical Co. Ltd., Kyoto,
Japan): octyldodecyl lactate:glycerin:sodium HA=100:45:30: 0.2 as
weight ratio of composition, was prepared as described previously
[17–19].
2.3. The AD model
BALB/c mice were sensitized on days 0 and 7 by an intraperitoneal
injection of 25 μg OVA and 1mg of alum (Imject Alum; Thermo Fisher
Scientific, Waltham, MA) in 300 μl of PBS. On days 14, 19, and 24, a
hydrogel patch (1×2 cm2) containing DW or OVA (100 μg) was ap-
plied to the auricle skin, covered with a wound management film to
allow for better skin adherence, and left for 24 h. The mouse skin was
treated with DBP solution in Tween 80 (1:1 ratio) every day during the
AD induction period. The detailed protocols are shown in Fig. 1A. Skin
and blood samples were collected on day 26 (Fig. 1A). Compound 22, a
small molecule CCR4-specific antagonist, was synthesized based on the
published information as described previously [21].
2.4. Histochemistry
Skin sections were stained with HE as described previously [22].
Acanthosis was evaluated by measuring the epidermal thickness on the
ear skin sections. The skin sections were also stained with toluidine blue
as described previously [20]. We counted mast cells between the car-
tilage and squamous epithelium in five random sites (×400) of a to-
luidine blue–stained ear section under a light microscope to obtain the
mean cell number per site.
2.5. ELISA
Serum total IgE levels were measured using an ELISA kit purchased
from Biolegend (San Diego, CA) and following the manufacturer’s in-
structions.
2.6. Isolation of cells
Skin samples were incubated for 60min at 37 °C in RPMI1640
supplemented with 0.24mg/ml collagenase A (Roche; Basel,
Switzerland), and 40 U/ml DNase I (Thermo Fisher Scientific). After
shaking vigorously, the resulting suspensions were filtered through a
70-μm cell strainer. Splenocytes were obtained by mashing spleens
through a 70-μm cell strainer, followed by erythrocyte lysis with an
ACK lysis buffer (150mM NH4Cl, 10mM KHCO3 and 0.1 mM Na2EDTA,
pH 7.2).
2.7. Flow cytometric analysis
We purchased fluorescence-labeled anti-CCR4 (clone 2G12), anti-
CCR3 (clone J073E5), anti-IL-4 (clone 11B11), anti-CD45 (clone 30-
F11), and anti-CD4 (clone GK1.5) from BioLegend and anti-siglec-F
from BD Biosciences (San Diego, CA). Cells were incubated for 30min
with a mixture of anti-CD45 and anti-CD4, anti-CCR4, anti-CCR3, or
anti-siglec-F. For intracellular staining, cells were then fixed and per-
meabilized (Cytofix/Cytoperm kit; BD Biosciences) and subsequently
stained intracellularly with anti-IL-4. After washing, cells were im-
mediately analyzed on a BD LSR Fortessa (BD Biosciences) and ana-
lyzed with the FlowJo software (Tree Star Inc., Ashland, OR). For IL-4
staining, cells were stimulated with phorbol 12-myristate 13-acetate
and ionomycin for 4 h.
2.8. Real-time PCR
Quantitative real-time PCR was performed on an ABI7000 (Applied
Biosystems, Foster City, CA) using a Kapa SYBR Fast qPCR Kit (Kapa
Biosystems, Woburn, MA) according to the manufacturer’s protocol.
The PCR conditions were 60 °C for 20min, 94 °C for 5min, and then 40
cycles of 94 °C for 30 s (denaturation) and 55 °C for 30 s (annealing
extension). The primers for IL-4, IL-17 A, IFN-γ, CCL17, CCL22, and
GAPDH were described previously [20]. The other primers used were as
follows: +5′-CAGCTAGTTGTCATCCTGGTCTTC-3′ and ―5′-GCCGATG
ATGTCTCTCAAGTGA-3′ for TSLP.
2.9. Statistical analysis
The procedure has been described previously [23]. Briefly, Student's
t-test was performed to analyze differences between the two groups.
One-way analysis of variance with the Holm post hoc test was per-
formed for multiple groups. We considered P<0.05 as statistically
significant.
3. Results
3.1. DBP induces TSLP, CCL17, and CCL22 expression in skin lesions of
BALB/c mice
Our previous studies have shown that a hydro gel patch promotes
skin penetration of antigenic proteins and induces antigen-specific Th2
responses more efficiently than a gauze patch [17–19]. Therefore, we
used the hydrogel patch as a transcutaneous delivery device for OVA as
an antigen. BALB/c mice were sensitized with OVA and alum, which
elicits antigen-specific IgE production, and then the hydrogel patch
containing OVA with or without DBP treatment was applied to the
auricle skin (Fig. 1A). Because DBP was reported to induce the ex-
pression of TSLP, which is an inducer of Th2-attracting chemokines
CCL17 and CCL22 [11,12,14–16], we first examined the effect of DBP
on the expression of TSLP, CCL17, and CCL22 in the skin lesions. As
shown in Fig. 1B, DBP treatment alone significantly increased the ex-
pression levels of not only TSLP mRNA but also CCL17 and CCL22
mRNAs in the skin lesions. Furthermore, the combination of the hy-
drogel patch containing OVA and DBP treatment further increased the
expression levels of TSLP, CCL17, and CCL22 mRNAs in the skin lesions.
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3.2. Topical application of OVA and DBP efficiently induces allergic skin
inflammation in BALB/c mice
Next, we histologically evaluated the skin lesions induced by the
hydrogel patch containing OVA and DBP treatment. HE staining de-
monstrated increased ear swelling and epidermal hyperplasia in the
skin applied with the hydrogel patch containing OVA and DBP treat-
ment (Fig. 2A and B). In this context, we observed increased infiltration
of inflammatory cells in the skin lesions induced by the hydrogel patch
containing OVA and DBP treatment compared with PBS, OVA, or DBP
treatment alone (Fig. 2A). Using flow cytometry, we also analyzed cells
infiltrating the skin lesions. Th2 cells (IL-4+CD4+ cells) and eosino-
phils (CCR3+siglec-F+ cells) were highly increased in the skin lesions
induced by the hydrogel patch containing OVA and DBP treatment
(Fig. 2C). In addition, we confirmed that CCR4 was indeed expressed on
Th2 cells infiltrating in the skin lesions (Fig. 2D). Furthermore, tolui-
dine blue staining demonstrated significantly increased infiltration of
mast cells in the skin lesions (Fig. 2C). We also measured total IgE in the
blood samples of these mice. As shown in Fig. 2E, the combination of
the hydrogel patch containing OVA and DBP treatment markedly in-
creased total IgE levels.
3.3. Topical application of OVA and DBP induces acute AD-like skin lesions
in BALB/c mice
AD is a biphasic disease, including the acute phase predominated by
Th2 cytokines and the chronic phase predominated by Th1 cytokines
[24]. It has further been reported that IL-17 A is expressed only in acute
AD skin lesions [25], and IL-22 is expressed in both acute and chronic
AD skin lesions [26]. We therefore examined the expression of IL-4, IL-
17 A, IL-22, and IFN-γ in the skin lesions using real-time PCR. IL-4 and
IL-17 A mRNAs, but not IFN-γ mRNA, were significantly increased in
the skin lesions induced by the hydrogel patch containing OVA and DBP
treatment (Fig. 3). In addition, IL-22 mRNA was significantly increased
in the skin lesions induced by the hydrogel patch containing OVA and
DBP treatment. Because CCR4 is also expressed by regulatory T (Treg)
cells [27], we examined the expression of Foxp3 mRNA, the Treg cell
marker. Foxp3 mRNA was not significantly increased in any skin le-
sions, including those induced by the hydrogel patch containing OVA
and DBP treatment (data not shown). Collectively, these results de-
monstrate that the combination of the hydrogel patch containing OVA
and DBP treatment is able to efficiently induce allergic skin in-
flammation with features of skin lesions similar to the acute phase of
human AD
3.4. Compound 22, a CCR4 antagonist, ameliorates AD-like skin lesions
To examine the role of CCR4 in the present AD model, we used
Compound 22, a selective CCR4 antagonist. We previously demon-
strated that Compound 22 showed no cross reactivity to almost all
human and mouse chemokine receptors by using a panel of murine L1.2
cells that stably express human and mouse chemokine receptors [21].
As shown in Fig. 4A, the cutaneous administration of Compound 22
dose-dependently inhibited Th2 cell infiltration into the AD-like skin
lesions induced by the topical application of OVA and DBP. Compound
22 at 100 and 500 μg/site also significantly inhibited eosinophil in-
filtration into the AD-like skin lesions (Fig. 4A). Consequently, Com-
pound 22 dose-dependently reduced the ear and epidermal thickness
(Fig. 4B and C). We also measured total IgE in the blood samples of
these mice. As shown in Fig. 4D, Compound 22 at 500 μg/site
Fig. 1. Induction of TSLP, CCL17, and CCL22 expression by a
hydrogel patch containing OVA and DBP treatment. (A) The
experimental protocol for induction of allergic skin in-
flammation. BALB/c mice were sensitized on days 0 and 7
with an intraperitoneal injection of OVA and alum. On days
14, 19, and 24, a hydrogel patch containing DW or OVA was
applied to the auricle skin. The auricle skin was treated with
DBP every day during the AD induction period. Skin and
serum samples were collected on day 26. (B) The mRNA ex-
pression of TSLP, CCL17, and CCL22 in skin lesions was ex-
amined by real-time PCR. Data are expressed as the
mean ± SE of results from nine mice. *P < 0.05 and **P <
0.01.
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significantly reduced the elevated total IgE levels. These results de-
monstrate that CCR4 antagonists may prevent or treat AD-like skin le-
sions.
3.5. Effect of Compound 22 on AD-related gene expression in AD-like skin
lesions
Th2-attracting chemokine CCL17 is regarded as a valuable bio-
marker for AD, and corelates with disease severity in AD [7,8].
Fig. 2. Allergic skin inflammation induced by a hydrogel patch containing OVA and DBP treatment. (A) HE staining. (B) Ear and epidermal thickness in the skin. Data
are expressed as the mean ± SE of results from six mice. (C) Cells in the inflammatory skin were analyzed by flow cytometry using the CD45 gate. Th2 cells:
CD4+IL-4+; Eosinophils: CCR3+siglec-F+. Mast cell numbers were determined by toluidine blue staining. Data are expressed as the mean ± SE of results from six
mice. (D) CD4+IL-4+ Th2 cells were analyzed for CCR4 expression by flow cytometry. The representative data are shown from at least three independent ex-
periments. (E) Quantification of serum total IgE. Data are expressed as the mean ± SE of results from seven mice. *P < 0.05 and **P < 0.01. Scale bar = 50 μm.
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Therefore, we examined the effect of Compound 22 on the expression of
AD-related genes, such as Th2-attracting chemokines and inflammatory
cytokines, in the AD-like skin lesions induced by the topical application
of OVA and DBP. As shown in Fig. 5, Compound 22 dose-dependently
reduced the elevated expression of Th2-attracting chemokines, such as
CCL17 and CCL22, in the AD-like skin lesions. Simultaneously, Com-
pound 22 at 500 μg/site significantly reduced the elevated expression of
inflammatory cytokines, such as TSLP, IL-4, and IL17 A.
4. Discussion
In this study, we combined DBP treatment and a hydrogel patch as a
transcutaneous delivery device for OVA in the classical OVA-sensitized
mouse model. We found that the topical application of OVA and DBP
efficiently induced AD-like skin lesions in BALB/c mice. Furthermore,
we demonstrated the therapeutic effect of Compound 22, a CCR4 an-
tagonist, on this AD mouse model.
Recently, it has been reported that DBP induces TSLP expression in
the skin and acts as an adjuvant for Th2 responses [14–16]. The in-
duction of TSLP expression is also considered to be one of the most
important mechanisms leading to the adjuvant effect of DBP. Accord-
ingly, TSLP has been shown to induce several allergy-related genes,
including Th2-type cytokines and Th2-attracting chemokines, and is
now regarded as a master regulator of Th2 inflammatory responses in
allergic diseases. In this study, we have corroborated previous findings
and demonstrated that the addition of DBP treatment promotes the
development of AD-like skin lesions by the hydrogel patch containing
OVA; the expression of TSLP together with IL-4, CCL17, and CCL22
(Figs. 1B and 3); the increase in ear and epidermal thickness (Fig. 2A
and B); the production of total IgE (Fig. 2D); and the infiltration of Th2
cells, eosinophils, and mast cells (Fig. 2C). The induction of TSLP ex-
pression seems to be highly important for the induction of CCL17 and
CCL22 and the subsequent infiltration of CCR4-expressing Th2 cells in
AD skin lesions. Thus, TSLP as an effective adjuvant may be potentially
useful for developing animal models for allergic diseases.
The OVA-sensitized mouse model is one of the most standard
models of AD. Repeated sensitization with a gauze patch containing
OVA induces allergic skin inflammation, which has pathological fea-
tures similar to the acute phase of human AD [28–30]. However, this
model using the gauze patch requires multiple sensitizations over an
extended period of time (usually 7 weeks) to induce the AD-like skin
lesion. More recently, we have developed an AD mouse model using a
hydrogel patch that can efficiently promote skin penetration of anti-
genic proteins and Staphylococcus aureus δ-toxin as a mast cell activator
to shorten the period necessary to induce AD-like lesions [20]. Al-
though the topical application of OVA and δ-toxin by the hydrogel
patch induced AD-like skin lesions by three weeks in BALB/c mice, the
AD-like skin lesions exhibited relatively mild inflammatory responses
without significant hyperplasia. Therefore, in this study, we combined
DBP as a TSLP inducer in our previous model using the hydrogel patch,
and were able to induce more severe AD-like skin lesions with hyper-
plasia. IL-22 is a key regulator of keratinocyte differentiation and epi-
dermal hyperplasia in skin diseases such as AD and psoriasis [31]. IL-22
is also preferentially produced by Th17 cells, although IL-22 is pro-
duced by a unique subset of cells, named Th22 cells, in humans but not
in mice [31]. Indeed, in the present study, the expression levels of IL-22
and IL-17 were increased in AD-like skin lesions (Fig. 3), and the ex-
pression levels of IL-22 and IL-17 were much higher than those in our
previous model using δ-toxin [20]. Thus, the infiltration of Th17 cells
expressing IL-22 and IL-17 may be involved in aggravation of AD-like
skin lesions including hyperplasia in the present AD model. Further-
more, it has been reported that Th17 cells, as well as Th2 cells, dom-
inantly express CCR4 [5,32,33], and CCL17, but not CCL22, is ex-
pressed in endothelial cells of AD skin lesions [8,34]. Thus, CCL17
seems to be primarily responsible for the infiltration of Th17 cells into
AD skin lesions. Consistent with this notion, although we found sig-
nificantly increased expression of CCL17 in the AD-like skin lesions
(Fig. 1), no marked difference was observed in the expression levels
between the present AD model and our previous model using δ-toxin
[20]. In this regard, because Th17 cells express CCR6 in addition to
CCR4 [35], CCR6 may also be associated with the infiltration of Th17
cells. The role of CCR6 in the present AD model remains to be eluci-
dated.
We have previously shown that serum CCL17 levels positively cor-
relate with disease severity in AD patients [7,8]. CCL17 is now regarded
as a useful biomarker to monitor AD disease activity during therapy.
Furthermore, we have demonstrated that CCL17 is involved in the de-
velopment of AD-like skin lesions using CCL17-transgenic mice and
CCR4-deficient mice on the BALB/c background [20,36]. However,
initial studies employing CCR4-deficient mice on the C57BL/6 back-
ground only demonstrated a minor role of CCR4 in the development of
AD-like skin lesions [27,37]. One reason for the discrepancy between
the previous studies and our studies may probably be due to the dif-
ference in the genetic background of CCR4-deficient mice. In addition,
because these previous studies used the classical OVA-sensitized model
using the gauze patch, we have also compared the expression levels of
CCL17 in AD-like skin lesions between the present AD model and the
classical model using the gauze patch. As a result, the expression levels
of CCL17 in the classical model were much lower than those of our
present model (data not shown). Thus, the discrepancy also may be
partly due to the procedures used for the induction of AD-like skin
Fig. 3. Cytokine expression in AD-like skin lesions. The mRNA expression of IL-
4, IL-17 A, IL-22, and IFN-γ in skin lesions was examined by real-time PCR. Data
are expressed as the mean ± SE of results from nine mice. *P < 0.05 and
**P < 0.01.
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lesions.
AD is currently considered a biphasic disease with a predominant
Th2 response in the acute phase, and a switch to a Th1 response in the
chronic phase [24]. In the acute phase, Th2 cells are predominantly
found in the skin lesions and produce IL-4, IL-5, and IL-13, which are
responsible for IgE production by B cells [24]. In the chronic phase, Th1
cells are increased in the skin lesions and produce IFN-γ, which con-
tributes to dermal thickness and hyperkeratosis [24]. These proin-
flammatory cytokines are considered to play a prominent role in AD
pathogenesis and to be potential therapeutic targets. Indeed, Dupi-
lumab, an anti-IL-4/13R mAb, has recently been approved by the FDA
for the treatment of moderate-to-severe AD, and tralokinumab, an anti-
IL-13 mAb has also been tested in a phase study [38]. In the present
study, we have demonstrated that a CCR4 antagonist ameliorates AD-
like skin lesions by inhibiting the infiltration of Th2 cells which produce
the Th2-type cytokines (Figs. 4 and 5). At any rate, because our present
AD model represents an acute AD model, the CCR4 axis is likely to play
a pivotal role at least in the acute phase of AD. Furthermore, Moga-
mulizumab, an anti-CCR4 mAb, has recently been reported to be tested
in a phase study to treat patients with asthma [39]. Thus, CCR4 may be
a potent therapeutic target for allergic diseases, including AD and
asthma.
In conclusion, we have demonstrated that the combination of the
hydrogel patch containing OVA and DBP treatment efficiently induces
allergic skin inflammation with skin lesions similar to those seen during
the acute phase of human AD only by three weeks in BALB/c mice.
Using this model, we have also demonstrated that cutaneous adminis-
tration of the CCR4 antagonist ameliorates the AD-like skin lesions.
Thus, our AD model employing the hydrogel patch may be potentially
useful for both basic studies of AD and developing new therapeutic
agents.
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